| Bioactivity | Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function[1]. | ||||||||||||
| Invitro | Dabuzalgron treatment increases ERK phosphorylation in a dose-dependent fashion with an EC50 of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron[1].Dabuzalgron (10 μM; 4 hours) protects NRVMs from cell death due to Doxorubicin (DOX)[1].Activation of the α1A-AR with Dabuzalgron (10 μM; 4 hours) mitigates the detrimental effects of DOX on mitochondrial membrane potential and abrogates the activation of important elements of the apoptotic response to mitochondrial damage[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | Dabuzalgron | ||||||||||||
| CAS | 219311-44-1 | ||||||||||||
| Formula | C12H16ClN3O3S | ||||||||||||
| Molar Mass | 317.79 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Dabuzalgron
CAS: 219311-44-1 F: C12H16ClN3O3S W: 317.79
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urina
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.